Abstract:Gliomas are the most common and recalcitrant intracranial tumors, approximately a quarter of which are classified as lower-grade gliomas (WHO II-III). Although the prognosis of lower-grade gliomas (LGGs) is significantly better than that of higher-grade gliomas, as a highly heterogeneous tumor type, the prognosis of LGGs varies greatly based on the molecular diagnosis. IDH wild-type used to be regarded as a dismal prognostic biomarker in LGGs; however, several studies revealed that IDH wild-type LGGs might not always be equivalent to glioblastoma (WHO IV). Hence, we hypothesize that underlying biological events in LGGs can result in different prognosis. In our study, transcriptome profiling was performed in 24 samples of LGG, and the results showed that the expression of phospholipase Cγ1 (PLCG1) was significantly correlated with IDH1/2 status and patients' clinical outcome. Furthermore, the cancer genome atlas (TCGA) and the Chinese glioma genome atlas (CGGA) databases verified that elevated PLCG1 expression was associated with tumor progression and poor survival in LGG patients. Moreover, PLCG1-targeted siRNA dramatically affected the growth, migration and invasiveness of IDH wild-type LGG cell lines. In in vitro and in vivo experiments, the PLC-targeted drug significantly suppressed the tumor growth of IDH wild-type LGG cell lines in vitro and tumors in mouse models. Taken together, our results demonstrated that higher PLCG1 expression was associated with tumor growth and worse prognosis in IDH wild-type LGGs and PLCG1 could serve as a potential therapeutic target for IDH wild-type LGG patients. The mRNA expression levels of phospholipase Cγ1 (PLCG1) are much higher in IDH wild-type (IDHwt) lower-grade gliomas (LGGs) than in that of IDH mutant (IDHmut) LGGs. Higher PLCG1expression in IDHwt LGGs indicates poor clinical outcome. PLCG1 amplification may act as the key mechanism of PLCG1 upregulation. Depletion of PLCG1 expression can inhibits proliferation and invasion of IDHwt LGG cell lines in vitro and in vivo. The PLC inhibitor U73122 may therefore be a potential therapeutical agent for IDHwt LGGs.

LncRNA IDH1-AS1 Suppresses Cell Proliferation and Tumor Growth in Glioma.

miR-19b-3p inhibits glioma progression via interacting with lncRNA HAGLR

Knockdown of Cyclin D1 Inhibits Proliferation, Induces Apoptosis, and Attenuates the Invasive Capacity of Human Glioblastoma Cells

Increased RLIP76 Expression in IDH1 Wild‑type Glioblastoma Multiforme is Associated with Worse Prognosis

Abstract. Mutation of the isocitrate dehydrogenase (IDH) gene is regarded a novel indicator for the prognosis of patients with glioma. However, the role of the IDH1 gene mutations in carcinogenesis and the mechanisms underlying their function in glioblastoma multiforme

IDH1R132H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

ID1 regulates U87 human cell proliferation and invasion.

In Silico Analysis Identifies Upregulated Lncrna DLGAP1-AS1 Which is Correlated to Poor Prognosis and Promotes Cell Proliferation in Glioblastoma

LEF1-AS1 Accelerates Tumorigenesis in Glioma by Sponging Mir-489-3p to Enhance HIGD1A

IDH1 mutation decreases the invasiveness of glioma by downregulating the expression and activity of TAZ

Inhibition of EGR1 Inhibits Glioma Proliferation by Targeting CCND1 Promoter

LncRNA IDH1-AS1 Links the Functions of C-Myc and HIF1α Via IDH1 to Regulate the Warburg Effect.

Gli1 Inhibition Induces Cell-Cycle Arrest and Enhanced Apoptosis in Brain Glioma Cell Lines

Overexpression of isocitrate dehydrogenase-1R¹³²H enhances the proliferation of A172 glioma cells via aerobic glycolysis.

The Long Non-Coding RNA IDH1-AS1 Promotes Prostate Cancer Progression by Enhancing IDH1 Enzyme Activity

Phospholipase Cγ1 (PLCG1) Overexpression is Associated with Tumor Growth and Poor Survival in IDH Wild-Type Lower-Grade Gliomas in Adult Patients

R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.

Silencing of Lncrna LBX2-AS1 Suppresses Glioma Cell Proliferation and Metastasis Through the Akt/GSK3β Pathway in Vitro.

Lnc-Nlc1-c Inhibits Migration, Invasion and Autophagy of Glioma Cells by Targeting Mir-383 and Regulating PRDX-3 Expression.

IDH1-R132H Mutation Radiosensitizes U87MG Glioma Cells Via Epigenetic Downregulation of TIGAR.